Eli Lilly and Company has reported 52-week data showing that simultaneous treatment with Zepbound, or tirzepatide, and Taltz, or ixekizumab, maintained or further improved outcomes in adults who have psoriasis or psoriatic arthritis alongside obesity or overweight. In TOGETHER-PsO, 30.6% of patients receiving the combination achieved both complete skin clearance and at least 10% weight loss at week 52 compared with 4.4% receiving Taltz alone. In TOGETHER-PsA, 39.2% of combination-treated patients achieved both an ACR50 response and at least 10% weight loss compared with only 1.7% in the Taltz monotherapy group.
The findings are notable because they treat obesity as part of the therapeutic problem rather than an unrelated comorbidity sitting beside inflammatory disease. Psoriasis and psoriatic arthritis frequently coexist with excess weight and metabolic dysfunction, and Lilly estimates that approximately 61% of U.S. patients with psoriasis and 65% of those with psoriatic arthritis also have obesity or overweight plus another weight-related condition. Higher body weight is associated with poorer outcomes in psoriatic disease, making the TOGETHER trials an attempt to test whether treating the inflammatory pathway and metabolic disease simultaneously produces broader benefits than controlling inflammation alone.
How much did adding Zepbound change psoriasis outcomes at one year?
TOGETHER-PsO enrolled 274 adults with moderate-to-severe plaque psoriasis. By week 52, 40.5% of patients receiving Taltz plus Zepbound achieved PASI 100, representing complete skin clearance, compared with 29.1% receiving Taltz alone. The combined endpoint requiring both PASI 100 and at least 10% body-weight reduction was achieved by 30.6% of combination-treated patients compared with 4.4% on Taltz monotherapy.
These one-year results follow statistically superior outcomes already demonstrated at the week-36 primary analysis. The 52-week assessments were prespecified exploratory objectives without multiplicity control, meaning they should be interpreted as durability and trajectory data rather than as a completely separate confirmatory statistical test. Lilly nevertheless reported that the improvements observed at week 36 were sustained or deepened through one year with no new safety concerns identified.
What happened in patients with psoriatic arthritis?
TOGETHER-PsA enrolled 271 adults with active psoriatic arthritis and obesity or overweight plus another weight-related comorbidity. At week 52, 43.7% of patients receiving Taltz and Zepbound achieved ACR50, representing at least a 50% improvement in the American College of Rheumatology response criteria, compared with 15.7% receiving Taltz alone. When the joint-response threshold was combined with at least 10% weight reduction, 39.2% of combination-treated patients achieved the endpoint compared with 1.7% on monotherapy.
One particularly interesting observation is that greater arthritis improvement had already appeared by week four, before patients would ordinarily be expected to achieve large clinically meaningful reductions in body weight. That raises the possibility that tirzepatide’s contribution may extend beyond mechanical benefits resulting from carrying less weight, potentially involving metabolic and inflammatory effects. The trials were not designed to prove a specific biological explanation for that early difference, so mechanistic interpretation remains an area for further research rather than a settled conclusion.
Why could obesity make psoriasis and psoriatic arthritis harder to control?
Adipose tissue is biologically active and produces signaling molecules capable of influencing systemic inflammation. Obesity can therefore coexist with inflammatory diseases in a way that potentially reinforces disease activity rather than functioning merely as additional body mass. Patients with obesity may also respond differently to some biologic therapies, while excess weight can worsen mobility, cardiovascular risk and overall functional burden in psoriatic arthritis.
The TOGETHER program attempts to address both sides of this interaction. Taltz blocks interleukin-17A, a cytokine central to inflammatory pathways involved in psoriasis and psoriatic arthritis, while Zepbound activates GIP and GLP-1 receptors to reduce appetite and body weight. Using the medicines concurrently therefore combines direct immunological therapy with metabolic treatment rather than asking one drug to solve both problems.
Did the combination improve anything beyond skin, joints and weight?
Lilly reported deeper reductions in high-sensitivity C-reactive protein, a measure of systemic inflammation, among combination-treated patients. Metabolic measures including body mass index, blood pressure, glucose, HbA1c, triglycerides and total cholesterol also remained improved or continued improving through week 52 compared with Taltz alone. These were prespecified exploratory assessments rather than the primary endpoints, but they reinforce the broader concept that patients with immune-mediated and metabolic disease may benefit from an integrated treatment strategy.
That approach could become increasingly relevant across immunology because obesity commonly overlaps with diseases such as psoriasis, psoriatic arthritis and other inflammatory conditions. Pharmaceutical development has traditionally organized treatments by specialty, with dermatologists prescribing one drug, rheumatologists another and metabolic disease managed separately. The TOGETHER results challenge that separation by suggesting that treating the metabolic disease can influence how successfully the inflammatory disease is controlled.
What safety signals appeared when Taltz and Zepbound were used together?
Adverse events in the combination groups were generally mild to moderate and consistent with the known safety profiles of the individual medicines. Events reported in at least 5% of combination-treated participants included nausea, diarrhea, constipation, injection-site reactions, vomiting, dizziness and headache. No new safety signal emerged through the one-year analysis.
The absence of a new signal is important because combining two chronic therapies can theoretically create additive tolerability problems even when the mechanisms are unrelated. Zepbound has well-established gastrointestinal adverse effects, while Taltz affects immune function and carries its own infection and hypersensitivity considerations. Longer-term real-world use would still be needed to understand adherence, treatment persistence and whether patients are willing to remain on two injectable therapies for extended periods.
Could Lilly eventually seek a formal combination indication?
Lilly has not announced in the August 31 release that the combination has received a new regulatory indication for psoriasis or psoriatic arthritis. Taltz and Zepbound remain approved according to their individual labels, and the TOGETHER studies provide evidence about concomitant use rather than automatically creating a new combination approval. Detailed 52-week findings are expected to be presented at future medical meetings and published in peer-reviewed journals.
The strategic implications are nevertheless considerable because Eli Lilly owns both products. That gives the company an unusual ability to develop an integrated immunometabolic treatment strategy without coordinating commercial interests between separate manufacturers. If future evidence supports additional indications or guideline recommendations, Lilly could potentially build a new treatment model around patients whose inflammatory disease and obesity are biologically and clinically intertwined.
